Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.3% - Time to Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) rose 6.3% during trading on Friday . The company traded as high as $3.21 and last traded at $3.19. Approximately 1,267,020 shares traded hands during trading, a decline of 54% from the average daily volume of 2,772,484 shares. The stock had previously closed at $3.00.

Wall Street Analysts Forecast Growth

TSHA has been the topic of a number of research reports. Canaccord Genuity Group raised their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Chardan Capital reissued a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Needham & Company LLC reissued a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Stock Performance

The business's 50-day moving average price is $2.06 and its 200-day moving average price is $2.39. The stock has a market cap of $664.01 million, a PE ratio of 5.14 and a beta of 0.44. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. acquired a new stake in Taysha Gene Therapies in the 3rd quarter worth approximately $201,000. Barclays PLC boosted its stake in Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company's stock worth $513,000 after purchasing an additional 193,046 shares in the last quarter. Geode Capital Management LLC boosted its stake in Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock worth $7,163,000 after purchasing an additional 682,273 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Taysha Gene Therapies in the 3rd quarter worth approximately $931,000. Finally, State Street Corp lifted its stake in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company's stock valued at $6,973,000 after acquiring an additional 150,647 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.